Niall O’Donnell fancies himself an archaeologist of the pharmaceutical persuasion. His firm, RiverVest Ventures, is scoping out the failed and forgotten drugs of big pharma, building companies to repurpose these benched meds for new indications.
The aim is to find drugs that have passed for safety in clinical trials, but may have shown limited efficacy in the initial disease they aimed to treat.